Brain Health

Never taking a break does more harm than good.

Integrated health system specialty pharmacies can improve patient care for non–multiple sclerosis neurologic conditions.

The small molecule effectively blocks cell death effector proteins, potentially rescuing cells from degeneration.

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

Cure Rare Disease's CRD-002 receives FDA orphan drug designation, advancing hope for SCA3 treatment with innovative oligonucleotide therapy.

With Oregon, Colorado, and New Mexico legalizing psilocybin-assisted therapy, opportunities for treatment are expanding.

The approved injection contains dihydroergotamine (DHE), which is the same medication used in hospitals, in a ready-to-use device.

These findings demonstrate an association that is independent of the disease’s genetic predisposition.

These results build off prior studies which demonstrated effectiveness of Bergen 4-day treatment (B4DT) in patients with panic disorders.

A recent study reveals a significant number of patients with psychiatric histories experience emergency visits after starting glucagon-like peptide-1 (GLP-1) medications, raising safety concerns.

New trials reveal xanomeline and trospium effectively alleviate schizophrenia symptoms, offering a novel treatment option with minimal adverse effects.

A survey showed that 92% of Americans are open to treatments that would slow disease progression.

In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.

Nipocalimab the first and only FcRn blocker approved in anti-acetylcholine receptor– or anti-muscle-specific kinase adults and children with generalized myasthenia gravis.

The breakthrough designation is supported by clinical data from ongoing phase 1/2 trials.

The safety profile of diazepam nasal spray among pediatric patients was consistent with older patients, supporting its use in this age group.

Nipocalimab with standard of care helped patients with generalized myasthenia gravis (gMG) maintain improvements in daily living and quantitative scores compared with placebo.

The future holds the promise of earlier diagnosis, more targeted therapies, and personalized neurological care, said speaker William D. Freeman, MD, FAAN.

Huntington disease (HD) has no curative treatments, therefore, there is a great need for therapies that can reduce or slow the progression of symptoms.

Numerical differences were observed as early as Month 1.

Advanced practice provider (APP) care models allow for health systems to better individualize care for patients, effectively meeting their needs.

Beth A. Malow, MD, MS, FAAN, said that pharmacists and health care professionals are at the frontlines of collaborating and raising awareness of climate change’s impacts.

Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.

Nilufer Ertekin-Taner outlines how embracing the biological complexity of neurodegenerative diseases can guide the development of precision therapies akin to those used in oncology.

BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.

Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.

About 59.2% of patients with tardive dyskinesia (TD) who completed the 48-week trial achieved remission.

Patients with a disorder from this family of neurodevelopmental conditions face a lack of approved treatment options, making radiprodil poised to transform the treatment paradigm.

Long-acting injectables offer a promising approach to schizophrenia treatment, but their effective use requires careful management and patient education.

Currently, EN001 is undergoing evaluation in a phase 1b trial.